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SUMMARY
The apolipoprotein E4 (APOE4) variant is the single greatest genetic risk factor for sporadic Alzheimer's disease (sAD). However, the cell-type-specific functions of APOE4 in relation to AD pathology remain understudied. Here, we utilize CRISPR/Cas9 and induced pluripotent stem cells (iPSCs) to examine APOE4 effects on human brain cell types. Transcriptional profiling identified hundreds of differentially expressed genes in each cell type, with the most affected involving synaptic function (neurons), lipid metabolism (astrocytes), and immune response (microglia-like cells). APOE4 neurons exhibited increased synapse number and elevated Ab 42 secretion relative to isogenic APOE3 cells while APOE4 astrocytes displayed impaired Ab uptake and cholesterol accumulation. Notably, APOE4 microglia-like cells exhibited altered morphologies, which correlated with reduced Ab phagocytosis. Consistently, converting APOE4 to APOE3 in brain cell types from sAD iPSCs was sufficient to attenuate multiple AD-related pathologies. Our study establishes a reference for human cell-type-specific changes associated with the APOE4 variant.
INTRODUCTION
Late-onset sporadic Alzheimer's disease (sAD) represents about 95% of all Alzheimer's disease cases (Alzheimer's Association, 2016) . sAD etiology is likely due to complex interactions among different brain cell types leading to interconnected cellular pathologies (De Strooper and Karran, 2016) . This dysfunction results in the pathological hallmarks of AD: senile plaques, neurofibrillary tangles, neurodegeneration, and cognitive dysfunction (Canter et al., 2016) . Critically important in the regulation of these processes is the balance between production and clearance of Ab peptides from the brain. Ab peptides, the main constituent of senile plaques, are produced mostly by neurons in an activity-dependent manner, and various astrocyte-and microglialdependent mechanisms are thought to promote breakdown or clearance of Ab from the brain (Bero et al., 2011; De Strooper and Karran, 2016) . In contrast to the long-standing view of Alzheimer's as a neuron-centric disease, recent genetic studies have identified numerous non-neuronal genes as important risk factors for sAD (Lambert et al., 2013) .
The earliest identified and most significantly associated genetic risk factor for sAD is the E4 allele of the APOE, which markedly increases AD risk relative to the APOE3 allele, while the APOE2 allele is considered protective (Corder et al., 1993; Lambert et al., 2013; Strittmatter et al., 1993) . A single amino acid difference between APOE3 (Cys112) and APOE4 (Arg112) results in a protein conformational change that affects binding to apolipoprotein receptors, lipids, and Ab (Liu et al., 2013 ). Brain APOE is mainly produced by astrocytes and secreted to the extracellular space, where it serves as the primary cholesterol carrier (Kim et al., 2009) . Importantly, APOE is expressed by other brain cell types including neurons and microglia, where its expression can be altered under neuropathological conditions (Keren-Shaul et al., 2017; Mathys et al., 2017; Xu et al., 2006) .
While the molecular etiology of AD driven by familial AD (fAD) mutations is relatively well understood, the specific impact of sAD risk factors including APOE4 remains much less clear. Studies using mouse models expressing humanized APOE isoforms, cell lines, and postmortem human samples have revealed multiple AD-related pathological phenotypes impacted by APOE4, including reduced Ab clearance, tauopathy, increased neuronal toxicity and mitochondrial dysfunction, though the cell-type-specific changes remain largely unexplored (Kim et al., 2009; Liu et al., 2013; Shi et al., 2017) . However, findings from animal models are often hampered by concerns about translatability to humans due to species differences while studies using human cells are limited by accessibility to the relevant cell types and an inability to model complex disease in vitro (Calcoen et al., 2015) . Recent advances in genome editing and differentiation protocols for generating 2D and 3D cultures from human induced pluripotent stem cells (iPSCs) now allow for a more systematic examination of APOE4 effects on the different brain cell types in a human in vitro model (Paquet et al., 2016; Raja et al., 2016; Ran et al., 2013; Wang et al., 2018) .
To better understand how APOE4 affects major brain cell types involved in AD pathogenesis, we utilized CRISPR/Cas9 to create isogenic iPSC lines harboring homozygous APOE4 alleles from unaffected parental APOE3 cells. We found that APOE4 iPSC-derived neurons, astrocytes, and microglia-like cells recapitulated phenotypes associated with AD at multiple levels. The critical role for APOE4 in AD pathogenesis is underscored by our observation that conversion of APOE4 in sAD patient-derived iPSCs to APOE3 was sufficient to alleviate most of the AD-related phenotypes observed in sAD iPSCderived neurons, glia, and organoids.
RESULTS

Generating Isogenic Homozygous APOE4 iPSCs
To enable systematic analysis of APOE4 effects on specific brain cell types ( Figure 1A ), we used CRISPR/Cas9 gene editing to generate APOE4 iPSCs from parental APOE3 cells derived from an unaffected subject. Successful editing resulted in a Cys112Arg substitution in the APOE protein product, which was verified by Sanger sequencing of colonies derived from single putatively edited cells ( Figure S1A ; STAR Methods). (F) Expression changes of cell-type signature genes in iPSC-derived corresponding APOE4 cell types were compared to APOE4 allele-associated eQTL effect sizes of those signature genes in postmortem human brain samples. The red dots in the plots showed overlap of significantly altered genes in both human brain samples and induced brain cell types. Among them, genes with concordant changes are pinpointed in the scatterplots. (G) Expression of the concordant genes in control and MCI brains was correlated with two AD phenotypical measurements: neocortical plaque density and clinical dementia rating (CDR). Statistical p values of Spearman's correlation are visualized in heatmaps, with blue or red colors indicating negative or positive correlation.
Whole-exome sequencing of our edited line as well as the parental iPSC line showed no unintended off-target mutations (Figures S1B-S1D), while karyotyping analysis revealed no chromosomal abnormalities in our isogenic lines ( Figure S1E ). Further, both parental and genome-edited iPSCs maintained comparable expression of pluripotency makers ( Figure S1F ).
Generation of Isogenic APOE iPSC-Derived Neurons, Astrocytes, and Microglia-like Cells Next, we derived neurons, astrocytes, and microglia-like cells from our isogenic APOE3 and APOE4 iPSC lines. We generated neurons following the neurogenin2-mediated differentiation protocol with some modifications ( Figure S2A ; STAR Methods). To obtain a pure population, we cultured neurons supplemented with conditioned media from control human astrocytes, rather than co-culturing in direct contact with astrocytes. Although we cannot exclude potential effects on neurons by APOE proteins in the conditioned media released by APOE3 astrocytes, this approach allowed us to investigate the effect of neuronal APOE variation in human-induced neurons. To generate astrocytes, we derived iPSCs into neural progenitor cells (NPCs), which were subsequently induced to differentiate into astrocytes, while microglia-like cells were generated using a recently described protocol (Chen et al., 2014; Muffat et al., 2016) (Figures S2B and S2C ; STAR Methods).
To obtain comprehensive transcriptional profiles of the three derived cell types, we next performed RNA sequencing (RNAseq). Pairwise correlation of the transcriptomes showed segregation of iPSC-derived neurons, astrocytes, and microglia-like cells into their corresponding cell types regardless of APOE status ( Figure 1B) . The transcriptome signature of each cell type clustered with the corresponding cell type derived from either human brain samples or iPSCs reported by other groups ( Figure S2D ; STAR Methods), validating the identity of our iPSC-derived neural and glial cells.
APOE3 to APOE4 Switch Dramatically Alters Transcriptomes of iPSC-Derived Neurons and Glia APOE variants were recently shown to affect gene expression in various cell types (Huang et al., 2017; Shi et al., 2017; Theendakara et al., 2016) . We analyzed the effect of converting APOE3 to APOE4 on expression of genes in iPSCs and iPSC-derived neural and glial cells. We found many genes differentially regulated by APOE genotype in each cell type ( Figure 1C) , with iPSCs showing the lowest number of differentially expressed genes (DEGs) ( Table S1 ). To identify genes whose expression is strongly correlated with APOE, we pooled all RNA-seq samples from all cell types of both genotypes and performed co-expression network analysis (STAR Methods). We found 857 genes with similar expression patterns to APOE ( Figure 1D ; Table S2 ). Gene ontology (GO) analysis indicated that expression of genes involved in lipid metabolism or immune responses, or associated with AD, was regulated synchronously with APOE ( Figure 1E ; Table S3 ). Considering the widespread effect of APOE4 on transcription, we asked whether DEGs observed in APOE4 cell types are regulated by a common set of transcription factors. Transcription motif analysis showed that, in addition to the three orphan motifs not associated with any known transcription factors, the motifs for nuclear factor 1 (NF1), activator protein 1 (AP-1), and nuclear factor kB (NF-kB) were markedly enriched in the promoters of genes in APOE module ( Figure S2E ). Among them, only the binding site for AP-1 was significantly enriched in DEGs affected by APOE4 in all of the induced brain cell types. We also performed microRNA (miRNA) motif analysis and found no common motifs in DEGs across the brain cell types and APOE co-regulated genes (Table S4) .
We then asked whether altered gene transcription by the APOE4 variant in iPSC-derived brain cell types parallels APOE4-dependent changes in human brain samples. This analysis allows us to identify ''gene hits'' and related pathways, potentially representing perturbed biological processes driven by the APOE4 variant. We compared our datasets with those from 880 human brain samples (normal controls and mild cognitive impairment subjects; STAR Methods). We selected ''signature'' genes for each cell type, with enriched expression in neurons, astrocytes, or microglia based on a previous report , and performed expression quantitative trait loci (eQTLs) analysis based on APOE4 genotype. These data were then compared to our RNA-seq results from each cell type. A significant number of neuronal signature genes exhibited concordant APOE genotype-dependent changes between the human samples and our iPSC-derived neurons (p = 0.042) (i.e., positively associated with APOE4 status in human and upregulated in APOE4 derived neurons, or vice versa). Among these coordinately regulated genes, more than half of them are known regulators of synaptic function (7 out of 12 genes, p = 2.59EÀ10), and most were negatively associated with APOE4 ( Figure 1F ). For astrocyte signature genes, eight genes were up-or downregulated based on APOE4 genotype in both human brain and iPSC-derived astrocytes ( Figure 1F ). Although this number of overlapping genes was not statistically significant (p = 0.23), it is interesting to note that three of those genes, PIK3C2A, CPNE3, and EFR3B, are known to be involved in phospholipid metabolic process (p = 5.39EÀ7). For microglia signature genes, there was a significant overlap between human brain and induced microglia-like cells (p = 1.6EÀ6) ( Figure 1F ). In contrast to neuronal signature genes, most of the microglia signature genes whose expression was affected by APOE4 in both human brain and microglia-like cells were upregulated. Strikingly, about half of them were associated with immune system process (p = 2.22EÀ9), suggesting that APOE4 impacts microglial functions related to the immune response. Expression of these APOE4-associated genes in each cell type showed significant negative or positive correlation with clinically defined AD phenotypes (neocortical plaque density and clinical dementia rating) in human patients ( Figure 1G ). Taken together, our transcriptome profiling showed that relative to APOE3, the APOE4 variant alters the expression of several pathways implicated in the development of AD in multiple brain cell types.
Increased Synapses, Early Endosomes, and Ab 42 Secretion in APOE4 Neurons In the brain, neurons play an essential role in AD pathology as both the main producers of Ab and the cell type most susceptible to damage. Despite this, the effect of neuronal APOE4 genotype on synaptic function and AD pathology is not clear.
Immunostaining results showed that neurons derived from both APOE3 and APOE4 iPSCs strongly expressed neuronal markers such as MAP2, but not neural progenitor markers such as nestin, after 4 weeks of induction ( Figure 2A ). RNA-seq revealed 445 genes that were significantly differentially expressed between APOE3 and APOE4 neurons (Figures 1E and 2B) . GO analysis of these DEGs revealed that cell proliferation-related transcripts were downregulated by APOE4, whereas neuron differentiationassociated genes were upregulated ( Figure 2B ). To investigate the possibility of different synaptic activity between APOE3-and APOE4-carrying neurons, we performed intracellular recording on APOE3 and APOE4 neurons. We observed increased miniature excitatory postsynaptic current (mEPSC) frequencies with indistinguishable mEPSC amplitudes in APOE4 neurons compared to APOE3 controls ( Figure 2C ), suggesting increased release of neurotransmitter or elevated synaptic density in APOE4 neurons. Consistent with the latter possibility, we observed an increase in number of synapses by immunostaining with the presynaptic marker, synaptophysin, and the postsynaptic marker, PSD-95, in APOE4 versus APOE3 neurons ( Figure 2D ). Increased synaptic activity has been shown to correlate with increased Ab production (Bero et al., 2011; Das et al., 2013) . To determine whether APOE4 neurons exhibit altered Ab release, we measured the levels of Ab secreted by APOE3 and APOE4 neurons by ELISA. Ab 42 levels were 20% higher from APOE4 cultures compared to APOE3 cultures, although Ab 40 levels were indistinguishable ( Figure 2E ).
In addition to elevated synaptic activity, endosomal abnormalities can elevate Ab production by active cleavage of amyloid precursor protein (APP) via b-site APP-cleaving enzyme 1 (BACE1), generating b-CTF, a precursor of Ab (Toh and Gleeson, 2016) . Further, increased number and/or size of early endosomes has been described in the brains of AD patients (Cataldo et al., 2000) . We examined early endosomes in neurons by immunostaining with an antibody against early endosome antigen 1 (EEA1). We found that the number of EEA1 puncta was higher in APOE4 neurons compared to their APOE3 counterparts. Total EEA1 levels, quantified as the product of ''mean intensity of signal'' and ''area covered by signal,'' were also increased in APOE4 neurons ( Figure 2F ). These findings indicate that induced neurons harboring the APOE4 allele exhibit disruption in pathways related to synaptic formation, associated with supernumerary synapses and increased frequency of synaptic transmission. Furthermore, APOE4 neurons contain a greater number of early endosomes than APOE3 controls.
APOE4 Astrocytes Exhibit Compromised Ab Uptake
Astrocytes are the major source of secreted APOE, supplying lipids such as cholesterol to other cell types, including neurons, in the brain (Kim et al., 2009; Liu et al., 2013) . Although astrocytes are known to have executive coordinating functions for neuronal activity and to play important protective roles in neurodegenerative disease (Sidoryk-Wegrzynowicz et al., 2011; Wyss-Coray et al., 2003) , the effects of APOE genotype on astrocyte function remain incompletely understood. Immunostaining data showed that both APOE3 and APOE4 iPSC-derived astrocytes strongly express the astrocyte-specific marker S100b ( Figure 3A ). We examined APOE protein levels in these cells by immunostaining, finding significantly reduced APOE intensity in APOE4 versus APOE3 astrocytes ( Figure 3A ). Immunoblotting confirmed less APOE expression in astrocytes harboring the APOE4 allele compared to APOE3 astrocytes ( Figure 3B ). Similarly, there (E) iPSC-derived astrocytes were fixed and incubated with filipin III for 1 hr followed by imaging. The bar graph represents the intensity of filipin III in the images. Scale bar, 10 mm. n = 9 images from three independent cultures. (F) iPSC-derived astrocytes were sorted based on the intensity of filipin III. The bar graph represents the intensity of filipin III in sorted cells. n = 6 per group. (G) iPSC-derived astrocytes were incubated with Ab 42 oligomers for 2 days, then residual Ab 42 was measured by ELISA. Right: the Ab 42 clearance index was calculated as described and normalized to APOE3 astrocytes. n = 9 per group. (H) Immunocytochemistry with Ab and GFAP antibodies in astrocytes. Right: relative immunoreactivity of Ab overlapped with GFAP in astrocytes. Scale bar, 10 mm. n = 8 images from three independent cultures. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars ± SEM. was a reduction of secreted APOE in APOE4 astrocytes cultures ( Figure 3C ). We then compared the transcriptomes of APOE3 and APOE4 astrocytes, noting that in parallel with reduced APOE protein, APOE transcription was also reduced by the APOE4 genotype. In total, we found 1,327 DEGs (418 genes upregulated; 909 genes downregulated) in APOE4 compared to APOE3 astrocytes ( Figures 1E and 3D ). GO analysis indicated that genes related to tissue development were downregulated whereas phosphate-containing compound metabolic processassociated genes such as CROT, LPGAT1, and PLPP3, which are known to be involved in lipid metabolism, were upregulated in APOE4 astrocytes ( Figure 3D ). Our transcriptome data further showed that the expression of numerous other genes with functions in lipid transport was decreased ( Figure S3A ).
Because one of the major functions of APOE is to transport lipids including cholesterol between cells, we explored whether APOE4 astrocytes are impaired in cholesterol transport. We measured the cellular levels of cholesterol in APOE3 and APOE4 astrocytes by staining with filipin III, a compound known to fluoresce upon binding to cholesterol. We observed stronger signals of fluorescent filipin III in APOE4 versus APOE3 astrocytes ( Figure 3E ). We next used flow cytometry analysis to better quantify the filipin III signal in individual cells, finding higher average fluorescent intensity in APOE4 compared to APOE3 astrocytes ( Figure 3F ). We then examined levels of cholesterol in cultured media, including another isogenic clone of APOE3 / APOE4 (APOE4 #2 ) to control for possible variance among colonies. We observed increased levels of secreted cholesterol in both APOE4 and APOE4 #2 astrocyte cultures compared to those in APOE3 cultures ( Figure S3B ), suggesting increased biosynthesis of cholesterol in APOE4 astrocytes. Astrocytes can uptake oligomeric and fibrillar Ab 42 in vitro and in vivo, which contributes to Ab clearance and prevents the detrimental effect of Ab accumulation seen in AD (Koistinaho et al., 2004; Wyss-Coray et al., 2003) . APOE forms lipoprotein complexes with various lipids including cholesterol, and it has been shown that APOE4-containing lipoproteins have impaired ability to bind and uptake extracellular Ab, compared to those of APOE3 (Kim et al., 2009; Liu et al., 2013) . However, it has not been directly or conclusively determined whether APOE4 impacts the ability of astrocytes to uptake Ab. To test this directly, we followed standard protocols by incubating iPSC-derived astrocytes with synthetic oligomeric Ab 42 for 2 days to allow sufficient time for Ab clearance (Wyss-Coray et al., 2003; STAR Methods) . To quantify Ab 42 uptake, we measured the fraction of oligomeric Ab 42 removed from the media after the 2-day incubation ( Figure 3G ; STAR Methods). We confirmed that our astrocytes did not secrete any detectable amount of Ab, ruling out endogenous Ab as a contributing source to the media (data not shown). Also, Ab treatment had no effect on cell viability or proliferation of APOE3 or APOE4 astrocytes ( Figure S3C ). APOE4 astrocytes were notably less efficient than APOE3 astrocytes in clearing Ab 42 from the media ( Figure 3G ). In complementary experiments to directly measure Ab 42 uptake by astrocytes, we performed immunostaining with antibodies against Ab and the astrocyte marker GFAP. Data indicated that less Ab 42 was taken up by APOE4 astrocytes ( Figure 3H ). Since lysosomal activity can affect Ab levels, we also examined lysosome-dependent degradation of Ab 42 by measuring intracellular Ab with or without lysosomal inhibitors following Ab 42 treatment. We observed increased Ab 42 accumulation following lysosome inhibition in APOE3 astrocytes compared to APOE4 astrocytes, suggesting reduced lysosome-dependent Ab 42 degradation in APOE4 astrocytes ( Figure S3D ). Taken together, our results indicate that harboring the APOE4 allele rather than APOE3 negatively affects the expression of APOE, alters cholesterol metabolism, and impairs uptake of Ab 42 in human iPSC-derived astrocytes.
APOE4 Microglia-like Cells Exhibit Inflammatory Gene Activation and Less Efficient Ab 42 Uptake Recent transcriptome analysis from human brain showed abundant expression of APOE in microglia (Gosselin et al., 2017) ; however, the potential effects of the APOE4 variant on microglial gene expression and function are not known. Microglia, distinguished by their elaborated morphology reflecting their phagocytic function, are important mediators of inflammation in the nervous system. Recent genetic and functional studies have highlighted critical roles for microglia in brain health and disease, and identified dysfunction of this cell type as an important driver of sAD progression (Efthymiou and Goate, 2017; Keren-Shaul et al., 2017) . Our iPSC-derived microglia-like cells clearly exhibit a ramified morphology characteristic of microglia . Noticeably, in the course of generating microglia-like cells, we observed that those harboring the APOE4 variant displayed fewer and shorter processes ( Figure 4A ). To gain further insights into potential effects of APOE4 on this cell type, we compared the transcriptomes of APOE3 and APOE4 microglia-like cells. We found 1,460 DEGs in APOE4 microglia-like cells compared to APOE3 cells, more than in any other cell type we examined ( Figures 1E  and 4B ). Interestingly, many more of the DEGs were downregulated (1,131 genes) than upregulated (329 genes) ( Figure 4B , left panel). While downregulated genes were shown to be strongly associated with cell movement and development, a third of the 329 upregulated genes in APOE4 microglia-like cells were associated with immune responses ( Figure 4B , right panel; Figure S4A ). These results suggest that APOE4 likely renders microglia more prone to promote inflammation, and may also alter their phagocytic behavior. To explore the latter idea further, we examined the phagocytic activity of these cells toward Ab. Since microglia take up Ab much faster compared to astrocytes (Fu et al., 2012) , we could monitor the uptake of fluorescently tagged Ab 42 (Ab 42 -555) by microglia-like cells in real time. During the 1 hr imaging period, we found that microglia-like cells harboring the APOE4 variant took up Ab 42 much more slowly than APOE3 cells (Figure 4C ; Videos S1 and S2).
We recently showed that cerebral organoids generated from iPSC lines harboring fAD mutations such as APP duplication (APP DP ) or PSEN1 mutation develop Ab aggregates and hyperphosphorylated tau in 2-3 months . To investigate the ability of induced microglia-like cells to impact AD pathology in 3D organoid systems, we co-cultured APOE3-or APOE4-carrying microglia-like cells with 2-month-old APP DP organoids that display Ab aggregates. After 1 month of co-culture, we observed that similar numbers of microglia-like cells were incorporated into APP DP organoids regardless of APOE genotype ( Figure S4B ). However, unlike microglia-like cells (without Ab treatment) in 2D-culture systems, APOE4 microglia-like cells embedded in APP DP organoids exhibited longer processes compared to APOE3 cells, without a change in process number ( Figures S4C and S4D ). Shorter process length of microglia in AD brains has been shown to positively correlate with microglial Ab uptake (Iaccarino et al., 2016; Sarlus and Heneka, 2017) . Therefore, these data suggested that microglia-like cells with the APOE4 variant may be less able to sense and respond to extracellular Ab. We observed that Ab accumulation in organoids containing APOE3 microglia-like cells was significantly less than that in APP DP organoids without co-cultured microglia-like cells ( Figure 4D ). However, APP DP organoids cocultured with microglia-like cells carrying the APOE4 allele exhibited more extracellular Ab aggregates than those co-cultured with APOE3 microglia-like cells ( Figure 4D ; Videos S3 and S4). Our data suggest that APOE4 negatively impacts several aspects of microglial function that potentially hinder the ability of microglia to clear extracellular Ab from AD brains, and may also influence the brain inflammatory profile. 
APOE4 Organoids Accumulate Ab and Exhibit Elevated Tau Phosphorylation
We next determined whether APOE4 organoids would develop hallmarks of AD similar to fAD organoids as described above (Figure 5A ). iPSCs used to generate organoids initially differentiate into NPCs and neurons, with astrocytes being detected at later time points (Quadrato et al., 2017) . Thus, organoids serve initially as a 3D neuronal model and later as a model incorporating both neurons and astrocytes, which each exhibit APOE4-dependent defects as described above. We found that unlike fAD organoids, which developed Ab aggregates after 2 months , APOE4 organoids did not develop detectable Ab accumulation by immunoblot assay at this time point ( Figure S5A ). Further, we found that APOE protein was undetectable in 3-month-old organoids, consistent with low expression of APOE in neurons, and few astrocytes at this stage of organoid development (Figure S5A ). As expected, there was an increase in the number of GFAP-positive astrocytes by 6 months of age, in parallel with increased APOE protein levels ( Figures 5B and S5B ). We found that the levels of APOE protein in APOE4 organoids were significantly lower compared to APOE3 organoids ( Figure 5B) ; both had a similar number of total astrocytes at this stage ( Figure S5B ). Remarkably, 6-month-old APOE4 organoids exhibited increased Ab accumulation and tau phosphorylation (p-S202/T205) compared to APOE3 organoids ( Figure 5B ). Immunostaining further demonstrated an increased number of Ab aggregates and elevated p-tau levels in 6-month-old APOE4 organoids compared to their APOE3 counterparts ( Figures 5C and 5D ).
Taken together, these data indicate that while APOE4 organoids exhibit delayed development of AD pathology relative to fAD organoids, the APOE4 variant alone is sufficient to cause AD hallmarks in cerebral organoids.
Converting APOE4 to APOE3 Attenuates AD-Related Phenotypes in Neurons, Glia, and Organoids Derived from sAD iPSCs Because APOE4 carries the highest known risk for sAD, we next tested whether converting APOE4 in iPSCs from an sAD patient to APOE3 was sufficient to ameliorate the molecular and cellular phenotypes of various iPSC-derived brain cell types we have uncovered. We used a similar CRISPR/Cas9 approach as described above to create isogenic iPSCs homozygous for APOE3 from sAD iPSCs homozygous for APOE4 ( Figure S6A ; STAR Methods). Karyotyping analysis confirmed that there were no detectable chromosomal rearrangements in these isogenic lines ( Figure S6B ). Whole-exome sequencing identified, other than the expected APOE4 to APOE3 change, a single variant in the TRIOBP gene causing replacement of Ala with Val ( Figures S6C and S6D ). TRIOBP is a TRIO and F-actinbinding protein that is known to be involved in actin cytoskeleton organization (Seipel et al., 2001) . While mutations of TRIOBP have been associated with autosomal recessive nonsyndromic deafness (Shahin et al., 2006) , there is no known link of TRIOBP with AD or any other neurodegenerative diseases. We then generated neurons, astrocytes, microglia-like cells, and organoids from these two iPSC lines. We first characterized induced neurons and found that APOE3 neurons exhibited reduced mEPSC frequencies and fewer synapses compared to APOE4 neurons ( Figures 6A  and 6B ). However, we did not observe a significant difference in the levels of secreted Ab 42 or Ab 40 ( Figure 6C ) between the two groups. Also, while converting APOE4 to APOE3 appeared to reduce the number of early endosomes in neurons, the effect did not reach significance (p = 0.06; Figure S6E ). In induced astrocytes, we found higher APOE protein levels and less accumulation of intracellular cholesterol in APOE3 than APOE4 astrocytes ( Figures 6D, S6F, and S6G) . Moreover, converting APOE4 to APOE3 enhanced the ability of astrocytes and microglia-like cells to uptake extracellular Ab (Figures 6E and 6F) . We also addressed the contribution of the APOE4 variant to Ab accumulation in sAD cerebral organoids and found that after 6 months of culture, APOE3 organoids displayed less Ab compared to age-matched APOE4 organoids ( Figure 6G ). Overall, these results indicate that most of the AD-related phenotypes observed in APOE4 iPSC-derived brain cell types and organoids could be reversed by editing to APOE3, confirming the central role of APOE4 in sAD pathology. 
DISCUSSION
Early Maturation of APOE4 Neurons Our transcriptional analysis revealed roughly equal numbers of up-and downregulated genes in iPSC-derived neurons. GO analysis showed that the expression of genes related to neuronal differentiation was upregulated by APOE4. Consistently, the increase in mEPSC frequency and number of synapses we observed in APOE4 neurons is suggestive of enhanced neuronal differentiation/maturation. We observed similar increases in synapse numbers in PSEN1 M146I iPSC-derived neurons (data not shown), indicating that early neuronal maturation could be a common phenotype of neurons with AD-linked mutations.
Neuronal signature genes whose expression was correlated with APOE4 genotype in both human and iPSC-derived samples were mostly downregulated and associated with synaptic functions ( Figures 1F and 1G) . One of the significantly downregulated genes, BDNF, was shown to have reduced expression in human APOE4 carriers, which paralleled cognitive impairment (Liu et al., 2015; Alvarez et al., 2016) . Our analysis of exome sequencing data from AD patients and unaffected controls showed a strong association between a SNP in the BDNF gene (E6K) with neocortical plaque density ( Figure S2F ; STAR Methods), although whether this SNP leads to loss of function remains to be clarified. Furthermore, elevating BDNF in the brains of AD rodent models also attenuated AD-related pathology (Zhang et al., 2015) . Thus, BDNF is a promising candidate that could account for some of the observed APOE4 neuronal phenotypes.
Our motif analysis identified high enrichment for transcriptional activator AP-1-binding sites in promoters of genes within the APOE module from human brain, and DEGs affected by APOE4 in our induced brain cells ( Figure S2E) . It was recently shown that E4 was the most potent APOE isoform in eliciting AP-1 activation in neurons (Huang et al., 2017) . Our analysis suggests that APOE4-dependent effects on AP-1 activation are not restricted to neurons, though further study will be required to determine whether common or distinct regulatory pathways operate in each cell type, and whether these mechanisms could be targeted for therapeutic development.
APOE4 Effects on Astrocytes
We found that the levels of APOE protein and mRNA were reduced in APOE4 astrocytes, suggesting that the APOE4 variant can negatively impact its own transcription. Consistently, studies from both humans and mouse models have reported similar reductions in APOE4 protein relative to APOE3 (Mooijaart et al., 2006; Shi et al., 2017) . In contrast, a recent study of iPSCderived astrocytes showed similar APOE levels in APOE3 versus APOE4 cells; however, these findings may be confounded by the use of non-isogenic backgrounds . Interestingly, we found that the reduced APOE4 mRNA and protein levels in iPSC-derived cell types were specific to astrocytes (data not shown), indicating the effect is cell-type specific.
Our gene expression analyses indicated the APOE4 variant regulates expression of numerous lipid metabolism and transport genes ( Figures 1E, 1F, 3D, and S3A) . One of the intriguing phenotypes we found was the accumulation of intracellular and extracellular cholesterol in APOE4 astrocyte cultures.
Cholesterol and other lipids are crucial for a wide range of cellular functions in the brain, and altered metabolism or transport appears to be associated with multiple pathological phenotypes in various neurodegenerative disorders (Gö ritz et al., 2002; Mauch et al., 2001) . Remarkably, the APOE4 variant appears to regulate both the metabolism and transport of lipids such as cholesterol, with potential effects on each of the three brain cell types. For instance, cholesterol-rich lipid rafts serve as a platform for APP processing to Ab (Cheng et al., 2007) , increased cholesterol can result in enlarged early endosomes (Marquer et al., 2014) , and altered cholesterol levels can affect gene expression (Goldstein et al., 2006) . Therefore, additional experiments from each of the APOE4 brain cell types have the potential to yield important insights into these aspects of APOE biology.
Importantly, we also found that APOE4 astrocytes were less efficient in uptake and clearance of Ab compared to their APOE3 counterparts. APOE4 is known to form smaller lipoprotein complexes with reduced affinity for Ab, as well as for APOE receptors, compared to APOE3 (Kim et al., 2009) . Combined with reduced astrocyte APOE4 protein expression, these factors would be predicted to strongly impair Ab clearance by astrocytes and other cell types. However, the role of APOE itself in Ab clearance remains contentious; some in vivo studies have shown that APOE is required for Ab clearance, while others have observed increased extracellular Ab clearance and attenuation of tauopathy in the absence of APOE (Holtzman et al., 1999; Koistinaho et al., 2004; Liao et al., 2014a; Shi et al., 2017) . Further work will be required to clarify this issue, as well as to determine whether the deficit in Ab uptake by APOE4 astrocytes is due solely to differences in levels and function of secreted APOE4 versus APOE3 protein, or if unrelated deficits in cellular function are more important.
Impaired Ab Uptake and Inflammatory Alterations in APOE4 Microglia-like Cells
In support of cell-intrinsic APOE4-dependent deficits in Ab uptake, we found that APOE4 microglia-like cells also exhibited reduced Ab uptake relative to their APOE3 counterparts, despite internalizing Ab much more quickly than astrocytes (1 hr for microglia-like cells in Figure 4C compared to 2 days for astrocytes in Figure 3H ). We further found that APOE4 microglia-like cells exhibited altered morphologies compared to APOE3 cells. In 2D culture (without Ab treatment), APOE4 microglia-like cells had fewer and shorter processes, while after embedding in 3D neuronal cultures (that produce Ab), the same cells had longer processes than their APOE3 counterparts. These observations are consistent with impairment in the ability of APOE4 microglia-like cells to effectively sense and/or respond to Ab in their environment. Given the importance of microglia surveillance and response functions to brain health, such impairment could have considerable detrimental effect for APOE4 carriers (Salter and Beggs, 2014) .
Multiple studies show a positive relationship between upregulation of immune-related genes and APOE4 genotype (Keren-Shaul et al., 2017; Mathys et al., 2017) . Our study suggests that carrying the APOE4 variant could be sufficient to convert resting microglia into immune-active. This alteration likely associates with morphological changes and may underlie the observed alterations in Ab uptake. It will be important to determine whether redirecting these cells from a ''reactive'' to a ''homeostatic'' state could restore their Ab uptake ability.
Among the upregulated immune genes we observed in APOE4 microglia-like cells was IRF8, which was shown to induce transcription of many immune-related genes and transform microglia into a reactive state (Masuda et al., 2012) . Thus, we asked whether the immune-related transcriptional changes in APOE4 microglia-like cells could be mediated via IRF8. Using available IRF8 chromatin immunoprecipitation sequencing (ChIP-seq) data from mouse bone marrow , we observed that upregulated genes indeed had higher IRF8 signals, consistent with an important role for this protein in APOE4-related transcriptional changes ( Figure S4E ). Interestingly, we also observed that expression of TREM2 (and its signaling adaptor TYROBP), which is crucial for microglial function and is itself a highly significant AD risk gene (Ulrich and Holtzman, 2016) , was positively correlated with APOE4 genotype ( Figures 1F and S4F ). This is consistent with recent studies showing increased levels of soluble TREM2 in cerebrospinal fluid of AD patients (Heslegrave et al., 2016) ; however, the mechanisms by which TREM2 and TYROBP are regulated by APOE variants will require further investigation.
Late Onset of Amyloid Accumulation in APOE4 Organoids Compared to fAD Organoids Increased levels of Ab and p-tau in APOE4 versus APOE3 organoids were apparent after 6 months of culture, which is relatively delayed compared to 2 months of culture for organoids with fAD mutations . We observed an increased number of synapses and early endosomes in APOE4 neurons, which could contribute to elevated Ab generation; however, the increase of Ab 42 secretion by APOE4 versus APOE3 neurons is much less than the 3-fold increase reported in fAD neurons versus controls (Paquet et al., 2016) . Astrocyte abundance in organoids also increases with duration of culture (Quadrato et al., 2017) , consistent with our ability to detect APOE protein at 6 month of culture, but not at 3 months ( Figure 4B ). Thus, both moderate increases of Ab secretion by neurons and impaired Ab clearance by astrocytes could contribute to Ab accumulation in APOE4 organoids at 6 months of age.
Amelioration of AD-Related Phenotypes by Switching APOE4 to APOE3 To complement our studies of APOE4-dependent defects in brain cell types, we edited the APOE4 allele of iPSCs derived from an sAD patient to APOE3. We were able to reverse most of the AD-associated phenotypes we examined by this APOE4 to APOE3 conversion, underscoring the critical importance of this genetic variant. However, we did not see a reduction in Ab 42 secretion from APOE3 versus APOE4 sAD neurons (Figure 6D) . Similarly, the reduction in early endosome numbers in APOE3 sAD neurons was not statistically significant, although there was a trend compared to APOE4 sAD neurons ( Figure 6E ). It is likely that additional factors in this sAD iPSC-derived cell line confound the AD-related pathologies we observe.
The APOE2 allele, which has been suggested to have a protective effect on the onset of AD, is also of great interest. However, compared to the APOE4 variant, our knowledge of the cellular and molecular alterations associated with APOE2 is quite limited. As such, it is not clear whether the effects of the APOE2 allele would be completely opposite to those of APOE4 on the examined cell types and organoids. Investigating the nature of protective effects of APOE2 on AD pathology using the human iPSC model systems warrants further study. In summary, our study suggests that APOE4 impacts AD pathology mainly through impairment of astrocyte-and microglia-mediated Ab clearance. Moreover, there are notable abnormalities associated with lipid metabolism in APOE4 astrocytes and potentially microglia. In this regard, targeting glia-mediated Ab clearance and lipid biogenesis/metabolism could be potential targets for therapeutic intervention. Furthermore, determining whether APOE4 mutation results in loss of functions or gain of toxic functions will be critical to tailor appropriate therapeutic interventions for APOE4 carriers. Our human APOE isogenic iPSCs offer a powerful set of useful tools to address these important questions.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human induced-pluripotent stem cells Unaffected (Coriell #AG09173, female, Age 75) and sporadic AD (Coriell #AG10788, female, Age 87) iPSC lines have been fully characterized and the APOE genotype was confirmed by sequencing. iPSCs were cultured on irradiated mouse embryonic fibroblasts (MEFs, MTI-GlobalStem) in human ES (hES) media [DMEM/F12, HEPES media (GIBCO) supplemented with 20% knockout serum replacement (KSR) (GIBCO), 1X non-essential amino acids (NEAA), 1X GlutaMAX, (Life Technologies), 12 nM beta-fibroblast growth factor (FGF2, PeproTech) and 0.1 mM 2-mercaptoethanol (Sigma-Aldrich)]. iPSCs were maintained at 37 C and 5% CO 2 in a humidified incubator.
METHOD DETAILS
Generation of isogenic iPSC lines
Preparation of the CRISPR/Cas9-ApoE sgRNA plasmid We prepared CRISPR/Cas9-APOE sgRNA plasmid following published protocol published (Ran et al., 2013) . Briefly, we designed a sgRNA sequence (5 0 -CCTCGCCGCGGTACTGCACC-3 0 ) within 10 nucleotides from the target site corresponding to amino acid 112 using the CRISPR Design tool (http://crispr.mit.edu). We annealed the oligomer pairs (5 0 -CACCGCCTCGCCGCGGTACTGCACC-3 0 and 5 0 -AAACGGTGCAGTACCGCGGCGAGGC-3 0 ) and cloned them into pSpCas9-2A-GFP (PX458) plasmid (Addgene #48138). Plasmid DNA was submitted for Sanger sequencing to confirm correct APOE sgRNA sequence. We also designed single-strand oligodeoxynucleotides (ssODN) to convert APOE4 to APOE3, or APOE3 to APOE4 with a silent mutation at the protospacer adjacent motif (PAM) site to prevent recurrent Cas9 cutting in edited cells. : APOE3 -> APOE4: GAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGC AGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGCGCGGCCGGCTGGTGCAGTACCGCGGCGAGGTGCAGGCCA TGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAG; APOE4 -> APOE3:GAGGA GACGCGGGCACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGGCT GGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGC AAGCTGCGTAAG. Electroporation iPSCs with 70 to 80% confluence were dissociated by treating with accutase (Thermo Fisher Scientific) and 10 mM ROCK inhibitor (Tocris) for 20 min. After spinning down iPSCs at 160 x g for 3 min, the number of cells was counted and 5 million cells were subjected to electroporation. Electroporation was performed using Nucleofector -Amaxa and Human Stem Cell Nucleofector Kit 1(Lonza) according to the manufacturer's instructions. In brief, cells were resuspended in 100 ml of reaction buffer from the kit and 7.5 mg of CRISPR/Cas9-APOE sgRNA plasmid and 15 mg of ssODN were added to cell suspension. After electroporation with A-23 protocol, we resuspended cells with hES media with 10 mM ROCK inhibitor and seeded them onto plates containing MEFs. Fluorescence-activated cell sorting (FACS) Two days after electroporation, we performed FACS to isolate GFP-expressing iPSCs. Briefly, dissociated cells using accutase/ ROCK inhibitor for 20 min were washed and resuspended with DPBS. Then, cells were filtered using Falcon polystyrene test tubes (#352235, Corning) and transferred to Falcon polypropylene test tubes (#352063, Corning). Sorting was performed by BD FACSAria IIU in FACS Facility at the Whitehead Institute. Sorted cells were suspended in recovery medium [hES medium with 1X PenicillinStreptomycin (P/S) (Gemini Bio-products) and ROCK inhibitor] and plated onto 6-well plates containing MEFs (50K cells/well).
Colony inspection
Each colony was transferred to one well of 12-well plate coated with MEFs and maintained until the colony grew big enough to be transferred to another 12-well plate. After the second transfer, iPSCs in the original plate were dissociated and genomic DNA was extracted. Primers (5 0 -CTGGAGGAACAACTGACCCC-3 0 and 5 0 -CTCGAACCAGCTCTTGAGGC-3 0 ) were used to amplify DNA in APOE gene and PCR products were submitted to GENEWIZ for Sanger sequencing. Karyotyping In order to identify and evaluate the size, shape, and number of chromosomes in iPSCs, we performed karyotyping after colony inspection. iPSCs were cultured on hESC-qualified matrigel (Corning) coated T25 cell culture flasks in mTeSR1 media (STEMCELL Technologies) until 60% confluence, and then sent to Cell Line Genetics for karyotyping.
Differentiation of iPSCs into neurons
We generated excitatory neurons from iPSCs according to published protocol . Briefly, iPSCs were prepared on matrigel coated 6-well plates at a density of 4 3 10 6 cells/well. Two hours later, lentivirus with rtTA and Ngn2-GFP expression vectors were suspended in mTeSR1 media with 2 mM thiazovivin (Tocris) and added to the iPSCs plates. After 24 hr, the culture medium was fully changed with N2(1X)/DMEM/F12/NEAA(1X) (Thermo Fisher Scientific) medium containing 10 ng/ml BDNF (Peprotech), 10 ng/ml NT-3 (Peprotech), 0.2 mg/ml laminin (Corning), and 2 mg/ml doxycycline (Sigma-Aldrich) to induce TetO gene expression. The following day, old media was removed and replaced with Neurobasal/B27(1X)/GlutaMAX(1X) (Thermo Fisher Scientific) medium containing 10 ng/ml BDNF, 10 ng/ml NT-3, 0.2 mg/ml laminin, 2 mg/ml doxycycline and 1 mg/ml puromycin (Millipore). Two days after puromycine treatment, Ngn2-GFP expressing cells were purified by FACS and plated onto matrigel-coated plates containing human astrocyte (ScienCell, #1850) in conditioned medium containing 10 ng/ml BDNF, 10 ng/ml NT-3, 0.2 mg/ml laminin, 2 mg/ml doxycycline, and 1 mg/ml puromycin. The next day, 1 mM Ara-C (Sigma-Aldrich) was added to cultured media. Three days after Ara-C treatment, media was removed and replaced with astrocyte conditioned medium containing 10 ng/ml BDNF, 10 ng/ml NT-3, 0.2 mg/ml laminin and 0.5 mg/ml doxycycline. One half plate volume of media was replaced with new media every 4 days until the cells were ready for experimental assays.
Differentiation of iPSCs into astrocytes iPSCs were cultured in 6-well plate coated with hESC-qualified matrigel (Corning) in mTeSR1 media until cells had reached $100% confluence. Then, cells were washed with DPBS and 2 mL of neural induction media [1:1 mixture of N-2 (DMEM/F-12 GlutaMAX, 1X N-2, 5 mg/ml insulin, 1 X NEAA, 100 mM 2-mercaptoethanol, and 1X P/S) and B-27 (Neurobasal medium, 1X B-27, 1X GlutaMAX, and 1X P/S media)] were added. Cells were treated with 1 mM Dorsomorphin and 10 mM SB431542 for 12 days, then passaged to new matrigel coated plates using accutase. Cells were cultured in neural maintenance media until the neural rosette structures became visible under the microscope (around days 16-24). Then, cells were passaged again with accutase and seeded at 4 3 10 6 cells/well density into matrigel coated 6-well plate. The day after passage, 20 ng/ml FGF2 (Peprotech) and 10 ng/ml BMP4 (Peprotech) were added into neural maintenance media. Media was changed every other day for 28 days and FACS were performed using GLAST antibody (Miltenyi Biotec) to purify astrocytes. After sorting, cells were seeded at 2.5 3 10 5 cells/well density into 6-well plate and
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
Statistical analyses were performed using Prism 6 (GraphPad Software). ANOVAs followed by Tukey's test, Dunnett's test or unpaired Student's t tests were used. All data are represented as mean ± s.e.m.
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